NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
MEDNAX, Inc. (NYSE: MD) Class Period: February 4, 2016 to July 27, 2017 Lead Plaintiff Deadline: September 10, 2018
Throughout the class period, MEDNAX, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's business model was not sustainable; and (2) Mednax's growth was in fact based upon suppressing physician compensation and enforcing non-compete agreements to deter physician defections. On April 20, 2017, Mednax announced negative financial results for the first quarter of 2017. Then on July 28, 2017, during an earnings call, Mednax announced that the Company failed to complete any acquisitions of anesthesiologist practices during the second quarter and disclosed that any future acquisitions were unlikely. Following this news, shares of Mednax fell from a close of $56.49 on July 27, 2017, to a close of $47.73 per share the following day.
Get additional information about the MD lawsuit: http://www.kleinstocklaw.com/pslra-c/mednax-inc?wire=3
Farmland Partners Inc. (NYSE: FPI) Class Period: March 16, 2016 to July 10, 2018 Lead Plaintiff Deadline: September 10, 2018
The complaint alleges that throughout the class period Farmland Partners Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that Farmland artificially increased revenues by making loans to related-party tenants who round-tripped the cash back to Farmland as rent; (2) that as a result, Farmland’s earnings during fiscal year 2017 were materially overstated; (3) the true extent and effect of Farmland’s non-arm’s length transactions; and (4) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked reasonable bases at all relevant times.
Get additional information about the FPI lawsuit: http://www.kleinstocklaw.com/pslra-c/farmland...inc?wire=3
National Beverage Corp. (NASDAQ: FIZZ) Class Period: July 17, 2014 to July 3, 2018 Lead Plaintiff Deadline: September 17, 2018
During the class period, National Beverage Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) National Beverage's sales claims and its supposed "proprietary techniques" lacked a verifiable basis; (2) the Company's Chairman and CEO engaged in a pattern of sexual misconduct between 2014 and 2016; and (3) as a result, National Beverage's public statements were materially false and misleading at all relevant times. On May 4, 2017, National Beverage issued a press release stating that it “employs methods that no other company does in this area—VPO (velocity per outlet) and VPC (velocity per capita).” National Beverage asserted that it “utilize[s] two proprietary techniques to magnify these measures and this creates growth never before thought possible.” Then on June 26, 2018 the Wall Street Journal reported that National Beverage had declined to provide the U.S. Securities and Exchange Commission with requested sales figures to clarify their sales claims. Then on July 3, 2018, the Wall Street Journal published an article reporting that two pilots had filed lawsuits alleging that National Beverage's CEO had sexually harassed them.
Get additional information about the FIZZ lawsuit: http://www.kleinstocklaw.com/pslra-c/national...orp?wire=3
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Class Period: April 29, 2016 to July 9, 2018 Lead Plaintiff Deadline: September 17, 2018
The lawsuit alleges ACADIA Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
Get additional information about the ACAD lawsuit: http://www.kleinstocklaw.com/pslra-c/acadia-p...inc?wire=3
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) Class Period: (1) Pursuant and/or traceable to the July 2017 Secondary Offering and/or (2) between March 8, 2017 and February 13, 2018 Lead Plaintiff Deadline: September 25, 2018
The complaint alleges that: (1) Tetraphase was increasing the patient enrollment in its IGNITE3 trial from 1,000 patients to 1,200 patients to meet the trial's primary endpoints; (2) the enrollment of more patients in the trial indicated that the existing population was inadequate to meet the trial's primary endpoints; and (3) consequently, Defendants' statements about Tetraphase's business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
Get additional information about the TTPH lawsuit: http://www.kleinstocklaw.com/pslra-c/tetrapha...inc?wire=3
AbbVie Inc. (NYSE: ABBV) Class Period: May 30, 2018 Lead Plaintiff Deadline: September 24, 2018
The complaint alleges that AbbVie issued false and misleading statements, in both press releases and filings with the U.S. Securities and Exchange Commission, regarding the results of the Company's $7.5 billion modified Dutch auction tender offer that expired on May 29, 2018 (the "Tender Offer"). Specifically, the complaint alleges that before the opening of trading on May 30, 2018, the Company announced that it expected to acquire 71.4 million of its shares tendered at or below $105 per share. As a result of this news, the price of AbbVie securities significantly increased. However, after the close of trading on May 30, 2018, the Company released materially different results for the Tender Offer due to certain omissions, announcing that the Company expected to acquire only those shares tendered at or below $103 per share. Upon this news, AbbVie shares fell from a close of $103.01 per share on May 30, 2018, to a close of $98.94 on May 31, 2018.
Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-c/abbvie-inc?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
